China, Brazil Should Not Be In AIDS Drug Patent Pool, Gilead Says
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - The number of partnerships among multinational pharmaceutical companies for HIV/AIDS drugs is on the rise, driven in part by the growing need for combination products to which no single company owns all the patents
You may also be interested in...
Gilead May Face Uphill Task With Sovaldi Despite Voluntary License Plan With Indian Generic Firms
Gilead may face unexpected speed bumps related to Sovaldi patents in India as it tries to extend the reach of its breakthrough HCV treatment via a combination of strategies, including voluntary licenses with Indian generics firms.
A Closer Look: Gilead’s Viread Donation To China
Gilead’s decision to donate Viread to Chinese HIV patients came at a time when China was updating its compulsory license rules. The U.S. company may have also been thinking about the potential ramifications for hepatitis B, a much larger market in China.
Back To The Future: Gilead Signs Up Four Indian Companies To License Late-stage AIDS Therapies
MUMBAI - In a strategic step looking to protect intellectual property rights while ensuring access to affordable life-saving medicines in developing nations, anti-HIV drugs specialist Gilead Sciences Inc. struck licensing deals July 12 with four India-based drug manufacturers - Hetero Drugs Ltd., Ranbaxy Laboratories Ltd., Strides Arcolab Ltd., and Matrix Laboratories Ltd. - for three Gilead drugs that are in late-stage clinical development